

A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy

Jennifer N. Bennett^{1†*}, Michael D. Blough^{1†}, Ian Mitchell², Lyle Galloway^{3,4}, and Ravinder Bains^{1,5,6†}

¹ATMA Journey Centers Inc., Calgary, Alberta, Canada

²Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada

³Department of Oncology, University of Calgary, Calgary, Alberta, Canada

⁴Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada

⁵Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

⁶Short Stay Unit, Peter Lougheed Centre, Calgary, Alberta, Canada

†These authors contributed equally and share first authorship

*Correspondence:

Jennifer Bennett

jennifer@atmajourney.com

Keywords:

Psilocybin, psychedelics, psilocybin-assisted therapy, psychedelic-assisted therapy, psilocybin safety, clinical protocols, adverse effects, blood pressure.

Abstract

This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin, are increasingly being recognized as a successful treatment option for many mental health concerns. In order to decrease the risks associated with its clinical use, more data is required regarding its physiological effects in healthy individuals. Safety assessments (heart rate, blood pressure, temperature, and ECG data), as well as adverse event evaluations were the primary outcome measures used to assess the physiological effects of 25 mg of psilocybin extract administered to 14 healthy individuals. We hypothesized that there would be a transient, clinically insignificant rise in both blood pressure and heart rate that would not result in any long-term adverse effects. No unexpected effects were observed, blood pressure and heart rate returned to normal as drug effects waned, and all participants had normal two-month follow-ups. Mean peak systolic and diastolic blood pressures during the psilocybin session were 145.93 ($SD = 19.01$) and 93.93 ($SD = 9.75$), respectively. While this represents a significant increase from baseline ($p < 0.0001$), a healthy cardiovascular system is capable of tolerating such levels for a longer time period than the brief duration of drug effects. Therefore, we suggest implementing focused and limited screening protocols to balance patient safety and

47 accessibility. Secondary outcomes of this trial centered on the subjective effects of psilocybin,
48 assessed via the QIDS-SR16 and the MEQ-30. There was a statistically significant decrease in
49 QIDS-SR16 scores from baseline scores ($M = 3.50$, $SD = 2.35$) to eight-week follow-up scores
50 ($M = 1.86$, $SD = 0.86$), $p = 0.018$. Mean MEQ-30 scores, assessed on day two and seven after the
51 psilocybin session, indicate participants had full mystical experiences.

52

53 **Introduction**

54

55 Over the last two decades, research on psychedelic drugs for the treatment of mental health
56 disorders has increased exponentially. Psilocybin – the psychoactive compound in
57 hallucinogenic mushrooms that are largely of the genus *Psilocybe* – has been gaining
58 prominence in the treatment of generalized anxiety disorder, treatment-resistant depression, and
59 end-of-life anxiety in palliative care patients (Carhart-Harris & Goodwin, 2017; Siegel et al.,
60 2021). Worldwide, countless studies have been conducted examining the efficacy of psilocybin
61 in treating such disorders, with many more clinical trials currently underway to assess its
62 efficacy in managing other indications such as eating disorders, post-traumatic stress disorder
63 (PTSD), substance use disorders, obsessive-compulsive disorder (OCD), chronic pain, and
64 migraines. While its efficacy has been broadly accepted by now, further exploration is
65 nonetheless warranted for potential contraindications and adverse events that psilocybin may
66 induce.

67

68 Psilocybin is classified as a Schedule I drug in the United States (DEA, 2020); this classification
69 has largely influenced the stigma that it has high abuse potential, no accepted medical use, and
70 can result in serious adverse events. However, research demonstrates contrary findings, insofar
71 as psilocybin not only has a low abuse potential but can actually aid in substance abuse
72 cessation and treat multiple mental health disorders, while maintaining a relatively positive
73 safety profile (Lowe et al., 2021). Nonetheless, as with any medication, establishing proper
74 screening and safety protocols is critical in order to implement this therapy responsibly.

75

76 When used properly, psilocybin has a favourable risk-benefit ratio. Mental illnesses are
77 devastating disorders that carry the potential risk of harm to self and harm to others, both directly
78 and indirectly; psilocybin, on the contrary, has a high therapeutic index of 641 (a better safety
79 profile than both aspirin and nicotine), and has significant potential to decrease the burden of
80 these disorders (Lowe et al., 2021). Although generally considered physiologically safe and
81 psychologically beneficial, it is important that clients are supervised during the acute psychedelic
82 experience so that support can be offered should any potential anxiety, trauma, impaired
83 decision-making, and/or rare physiological side effects arise. As with any pharmaceutical, there
84 are certain concomitant medications and medical conditions that should be avoided in order to
85 warrant the drug's safe use. There is the need to gather more data examining baseline physiology
86 in healthy individuals to demonstrate that psilocybin can be safely administered in a clinical
87 setting. From the results obtained in our Phase I safety trial, we aim to inform the development
88 of protocols for psilocybin-assisted psychotherapy.

89

90 Vital signs and adverse event assessments were the primary outcome measures in this trial. Such
91 assessments can help identify which populations present with an elevated risk, and thus for
92 whom extra caution would be advisable. A proper screening protocol can then be developed

93 from the evaluation of adverse events. Several studies have previously assessed the
94 cardiovascular effects of psilocybin, in which transient increases in blood pressure were
95 observed (Hasler et al., 2004; Daniel & Haberman, 2017; Carbonaro et al., 2018). Hasler et al.
96 (2004) also showed that ECG was unaffected with various doses of psilocybin; however,
97 Dahmane et al. (2021) showed a minor effect of 25mg on QTc prolongation, in which the effect
98 of 25mg of psilocybin meets a low level of concern (<10 ms) regarding non-cardiac medications
99 by the FDA. As such, this trial sought to further evaluate sympathomimetic effects including
100 heart rate, blood pressure, cardiac electrical activity via ECG, and temperature. Adverse event
101 assessments also included monitoring for side effects for up to two months after the psilocybin
102 session.

103
104 The secondary exploratory objective of this study examined the effects of psilocybin on both
105 mood and mystical experience. Two questionnaires – the Quick Inventory of Depressive
106 Symptomatology Self-Report 16-item (QIDS-SR16) and the 30-item Revised Mystical
107 Experience Questionnaire – were used as the assessment tools to measure these variables.
108

109 **Materials and Methods**

110 *Study Design*

111 This was an open label, single arm, single centre Phase I safety trial that took place at ATMA
112 Journey Centers in Calgary, Canada. Participants were recruited nationally, and during the
113 enrollment process, participants were screened by the Primary Investigator for eligibility based
114 on the criteria approved by Health Canada. Participants were followed for two months after the
115 psilocybin session. This trial was approved by The Health Research Ethics Board of Alberta
116 (HREBA) – Clinical Trials Committee (CTC).
117

118 *Investigational Product*

119 The psilocybin product, PEX010, was provided by Psilo Scientific Ltd. in the form of psilocybin
120 standardized extract powder, encapsulated in hydroxypropyl methylcellulose capsules. Each
121 capsule contained 25 mg of psilocybin and was manufactured in full compliance with Good
122 Manufacturing Practices (GMP) required to manufacture investigational medicinal products in
123 Canada.
124

125 *Participants*

126 During screening, applicants were evaluated for eligibility criteria, in which 14 participants were
127 selected. The criteria required that participants be aged 18-65 years of age, be physically and
128 mentally healthy as determined by a primary care physician via physical and mental
129 examinations, be a medical or mental healthcare provider with professional accreditation, have a
130 negative pregnancy test at study entry and prior to the psilocybin session if of child-bearing
131 potential, and agree to use adequate forms of birth control from study entry to 10 days after the
132 psilocybin session. Exclusion criteria included both active psychotic symptoms and a history of
133 psychotic symptoms, bipolar disorder, schizophrenia, first- or second-degree relatives with a
134 history of psychotic symptoms, bipolar disorder, or schizophrenia, the use of psychotropic
135 medications including SSRIs, SNRIs, MAOIs, or lithium, a diagnosis of either dementia or
136 delirium, a high risk for coronary artery disease, uncontrolled cardiopulmonary
137 disease/cardiovascular disease, uncontrolled hypertension greater than 140/90mmHg assessed on
138

139 three separate occasions, a history of QT prolongation or on concomitant medications carrying a
140 risk of QT prolongation, aneurysm, a history of intracerebral hemorrhage, hepatic cirrhosis,
141 hepatorenal disease, any other clinically significant medical condition or disease, suicide risk, or
142 have a known sensitivity or intolerability to psilocybin or its metabolites. This eligibility criteria
143 were developed based on previously researched contraindications and other potential
144 contraindications that require further research before psilocybin can comfortably be used by such
145 populations. Participants were required to sign an informed consent form before enrollment.
146

147 The criterion that participants must hold professional accreditation as a medical or mental
148 healthcare provider produced a unique opportunity to examine the effectiveness of psilocybin in
149 a clinical setting; healthcare workers who work directly with patients suffering from mental
150 illness are likely to be valuable judges of a treatment's utility and possess a constructive
151 perspective. Although not a measurable objective in this study, it gives the professionals
152 involved in the development of protocols and the implementation of this novel treatment a
153 practical understanding of how and why it is efficacious, as well as laying the foundation for
154 future research examining this as a formal objective.
155

156 As shown in Table 1, this study enrolled 14 participants aged 32-64. Participants were
157 predominately female (78.6%), with 77% of total applicants being female. Although this is
158 disproportionate, an analysis performed by the World Health Organization including 104
159 countries showed that 70% of the total population of workers in the health and social sector are
160 female (WHO, 2019).
161

162 *Outcome Measures*

163 The primary objective of this Phase I clinical trial was to collect data regarding the safety of
164 psilocybin when administered to healthy individuals. Safety was assessed by documenting vital
165 signs and recording adverse events (AEs) and serious adverse events (SAEs).
166

167 The secondary exploratory objective utilized two self-assessment questionnaires (the QIDS-
168 SR16 and the MEQ-30). These questionnaires were intended to evaluate the general nature of the
169 subjective effects occasioned by the consumption of psilocybin and to determine its impacts on
170 the participants' mental health following their experimental session.
171

172 *Safety Assessments*

173 For safety evaluations, SAEs (defined as any untoward medical occurrence that happens after
174 psilocybin treatment that either results in death, is life-threatening, requires in-patient
175 hospitalization, results in persistent or significant disability/incapacity, results in a congenital
176 anomaly or birth defect, or a loss of pregnancy) and all adverse events (defined as unfavourable
177 and unintended signs, symptoms, or disease associated with a treatment) were formally assessed
178 during the psilocybin session, as well as two days, seven days, and eight weeks following the
179 psilocybin session. During this eight-week time period, participants were also instructed to report
180 any SAEs immediately. AEs were assessed by severity (mild, moderate, severe, life-threatening,
181 or fatal). Specific AEs that were investigated include nausea, vomiting, headache, anxiety,
182 confusion, fatigue, and mania or psychotic symptoms. A subset of AEs – adverse events of
183 special interest (AESI) – that could be indicative of QT interval prolongation or cardiac
184 arrhythmias (including ECG abnormalities during the psilocybin session, sudden death, non-

185 postural syncope, palpitations, or seizures) were assessed to evaluate psilocybin's impact on
186 cardiac function. A second AESI involved the assessment of suicide risk via the following
187 behaviours: suicide, suicide attempts, self-injurious behaviour associated with suicidal ideation,
188 or suicidal ideation judged to be serious or severe in the opinion of the Principal Investigator.
189 Treatment emergent adverse events (TEAEs; defined as AEs with an onset after drug
190 administration and up to two days afterwards) were also assessed by severity, and included
191 assessments for nausea, vomiting, headache, anxiety, confusion, fatigue, and mania or psychotic
192 symptoms that emerged soon after the psilocybin session and lasted for longer than 24 hours
193 after cessation of drug effects. Adverse drug reactions (ADRs; defined as a serious adverse event
194 that is not identified in nature, severity, or frequency in the risk information set out in the product
195 monograph) were monitored, with special attention being paid to unexpected ADRs.

196
197 During the psilocybin session, blood pressure, heart rate, and temperature were measured every
198 hour, as well as when signs or symptoms warranted further vital sign measurement. 30-second
199 electrocardiogram (ECG) recordings were obtained every hour. Blood pressure and heart rate
200 were monitored using the Large Cuff Easy@Home Digital Upper Arm Blood Pressure Monitor,
201 FDA-cleared for over-the-counter use. Temperature was assessed via the FOR A IR42 Forehead
202 Thermometer, licensed by Health Canada. ECG recordings were obtained using the
203 KardiaMobile Six-Lead Personal EKG Monitor.

204 205 *Statistical Analysis*

206 The statistical analysis was completed using SPSS 29.0 and Prism 9.

207 208 **Results**

209
210 Table 2 summarizes the main results of this study. A t-test for dependent means was used to
211 assess the effect that psilocybin had on peak mean arterial pressure (MAP). To do this, a
212 corresponding MAP was calculated from each blood pressure measurement that was taken
213 during the psilocybin session, using the formula $MAP = DP + 1/3(SP - DP)$. The highest MAP
214 of each participant was documented and used to help determine the risk psilocybin poses for the
215 cardiovascular system. Figure 1 compares baseline to peak MAP. There was a statistically
216 significant effect $t(13) = -5.56, p < 0.001$, of psilocybin on MAP. Mean arterial pressure
217 increased from an average baseline of 91.55 mmHg ($SD = 7.59$) to an average peak of 110.76
218 mmHg ($SD = 12.15$) during the psilocybin session. Baseline MAP ranged from 79.67–104
219 mmHg, whereas peak MAP ranged from 93.33–126.67 mmHg.

220
221 A t-test for dependent means was conducted to assess if psilocybin had an effect on peak systolic
222 blood pressure (SBP). The highest SBP for each participant during the psilocybin session was
223 documented and these were compared to their baseline SBPs. Figure 2 compares baseline,
224 average, and peak SBPs in each participant. There was a statistically significant effect $t(13) = -$
225 $5.44, p < 0.001$. Systolic blood pressure increased from an average baseline of 121.5 mmHg
226 ($SD = 11.59$) to an average peak of 145.93 mmHg ($SD = 19.01$), demonstrating a likely effect of
227 psilocybin on SBP. Baseline SBP ranged from 102–140 mmHg, while peak SBP ranged from
228 126–193 mmHg.

229

230 A t-test for dependent means was conducted to assess the effect that psilocybin had on peak
231 diastolic blood pressure (DBP). The highest DBP for each participant during the psilocybin
232 session was documented and these were compared to their baseline DBPs. Figure 3 compares
233 baseline, average, and peak DBPs in each participant. There was a statistically significant
234 effect $t(13) = -5.54, p < 0.001$. Diastolic blood pressure increased from an average baseline of
235 76.57 mmHg ($SD = 7.38$) to an average peak of 93.93 mmHg ($SD = 9.75$), demonstrating a likely
236 effect of psilocybin on DBP. Baseline DBP ranged from 62-89 mmHg, while peak DBP ranged
237 from 77-109 mmHg.

238
239 A t-test for dependent means was conducted to assess the effect that psilocybin had on average
240 SBP. For each participant, all SBP data points collected during the psilocybin session were used
241 to calculate an average SBP. These averages were compared to baseline SBP (Figure 2). There
242 was a statistically significant effect $t(13) = -3.88, p = 0.002$. Systolic blood pressure increased
243 from an average baseline of 121.5 mmHg ($SD = 11.59$) to an overall average of 133.03 mmHg
244 ($SD = 13.68$); this is an average increase of 11.53 mmHg from baseline. Average SBP during the
245 psilocybin session ranged from 116.6-163.25 mmHg.

246
247 A t-test for dependent means was conducted to assess the effect that psilocybin had on average
248 DBP. For each participant, all DBP data points collected during the psilocybin session were used
249 to calculate an average DBP. These averages were compared to baseline DBP (Figure 3). There
250 was a statistically significant effect $t(13) = -3.98, p = 0.002$. Diastolic blood pressure increased
251 from an average baseline of 76.57 mmHg ($SD = 7.38$) to an overall average of 86.44 mmHg
252 ($SD = 8.08$); this is an average increase of 9.87 mmHg. Average DBP during the psilocybin
253 session ranged from 77-102.88 mmHg.

254
255 A t-test for dependent means was conducted to examine the effect of psilocybin on peak heart
256 rate. There was a statistically significant effect $t(13) = -4.97, p < 0.001$. Heart rate increased from
257 a baseline of 68.43 bpm ($SD = 7.94$) to an average peak heart rate of 91.57 bpm ($SD = 17.25$),
258 demonstrating a likely effect of psilocybin on heart rate. Baseline heart rate ranged from 56-84
259 bpm, while peak heart rate ranged from 78-143 bpm.

260
261 A t-test for dependent means was conducted to assess the effect of psilocybin on average heart
262 rate. There was a statistically significant effect $t(13) = -3.74, p = 0.002$. Heart rate increased from
263 an average baseline of 68.43 bpm ($SD = 7.94$) to an average of 81.21 bpm ($SD = 11.91$),
264 demonstrating a likely effect of psilocybin on average heart rate. Average heart rate during the
265 psilocybin session ranged from 72.83-112.8 bpm.

266
267 A t-test for dependent means was used to assess the effect of psilocybin on QTc interval.
268 Psilocybin did not produce a significant effect on QTc interval $t(13) = 2.15, p = 0.051$, with an
269 average baseline QTc interval of 419.21 ($SD = 19.37$) and an average maximum QTc interval of
270 406.64 ($SD = 16.76$). Baseline QTc intervals ranged from 392-453 and maximum QTc intervals
271 during the psilocybin session ranged from 366-437.

272
273 Temperature ranged from 35.9-37.5°C during the psilocybin session, with a mean of
274 36.85 °C ($SD = 0.32$).

275

276 A one-way repeated measures ANOVA was used to assess the effect of psilocybin on depressive
277 symptoms by assessing QIDS-SR16 scores before the psilocybin session and on day two, day
278 seven, and week eight after the psilocybin session. There was a significant effect on QIDS-SR16
279 scores across the different time periods $F(3, 39) = 3.80, p = 0.018$. According to the Tukey HSD
280 post hoc test, QIDS-SR16 scores after eight weeks ($M = 1.86, SD = 0.86$) were significantly
281 lower than baseline scores $3.50 (SD = 2.35)$. No significant differences in scores were seen
282 between baseline and day two, baseline and day seven, day two and day seven, day two and eight
283 weeks, or day seven and eight weeks. Day two post-psilocybin QIDS-SR16 scores had a mean
284 of $3.29 (SD = 2.27)$ and day seven post-psilocybin QIDS-SR16 scores had a mean of $2.21 (SD =$
285 $1.67)$.

286
287 A t-test for dependent means was conducted to determine if participants deemed their experience
288 more mystical in nature two days after vs. seven days after the psilocybin session via the MEQ-
289 30. There was not a significant difference seen between the two times $t(13) = 1.35, p = 0.202$.
290 The mean MEQ-30 score for two days after the psilocybin session was $3.77 (SD = 0.80)$, and the
291 mean MEQ-30 score for seven days after the psilocybin session was $3.67 (SD = 0.94)$. While
292 there is not a significant difference between these times, both means are representative of a full
293 mystical experience, which is determined by a score ≥ 3 . On day two, the scores ranged from
294 $2.6-4.93$, and on day seven the scores ranged from $2.2-4.93$. Overall, 11 of the 14 participants
295 had a full mystical experience.

296
297 The adverse events experienced were generally mild, expected, and occurred within two days
298 following the psilocybin session (Table 3). One participant experienced a severe headache during
299 this time, but it was manageable with Tylenol and Advil. After seven days, the only adverse
300 event experienced was mild anxiety by one participant, and no adverse events were present by
301 the eight-week follow-up.

302 303 **Discussion**

304
305 The most significant finding from this safety analysis was the effect psilocybin has on blood
306 pressure. Statistically significant elevations in both MAP, and systolic and diastolic blood
307 pressure were seen. However, this observed increase in blood pressure and heart rate were
308 expected adverse events, based on the known effects that classic psychedelics have on the
309 cardiovascular system via certain serotonergic receptors (e.g., $5-HT_3$ and $5-HT_{2A}$) (Rossi, Hallak,
310 Bouso Saiz, & Dos Santos, 2022). These receptors are not only directly related to the modulation
311 of heart rate, but also affect vasoconstriction. While these events were expected, it was also
312 predicted that such events would be transient and manageable in healthy participants, and this
313 has been documented in other studies such as in Daniel & Haberman (2017) and Carbonaro,
314 Johnson, Hurwitz, & Griffiths (2018).

315
316 While Hasler et al. (2004) did not find an overall significant main effect of psilocybin on MAP,
317 they extended their analysis further to assess whether blood pressure increased at a particular
318 time during psilocybin treatment; it was found that MAP was significantly elevated at 60 minutes
319 post-administration. In a similar manner, DBP was only significantly elevated at 90 minutes
320 post-administration. Yu et al. (2022) conducted a meta-analysis that analyzed psilocybin's effect
321 on the cardiovascular system as a secondary outcome. Compared with placebo, psilocybin

322 treatment was associated with a significant increase in both systolic and diastolic blood pressure;
323 an average increase of 19.00 mmHg and 8.66 mmHg was observed, respectively. This is
324 comparable to the results of our study, in which there was an average increase in systolic and
325 diastolic blood pressure from baseline by 11.53 mmHg and 9.87 mmHg, respectively. In a
326 manner similar to the aforementioned studies, all 14 participants' blood pressures and heart rates
327 in our study returned to baseline levels as drug effects waned, and these levels remained normal
328 at the eight-week follow-up appointments.

329
330 Another parameter of interest was the QTc interval. Dahmane, Hutson, & Gobburu (2021)
331 conducted a study to determine the concentration-QTc relationship of psilocybin/psilocin. They
332 determined that in the high dose group (ranging from 42-59 mg), at the time of C_{max} , the upper
333 limit of the 90% confidence interval of the mean ΔQTc exceeded the threshold level of
334 regulatory concern (10 ms) at a psilocin concentration of 31.1 ng/mL. Such doses are much
335 larger than the therapeutic psilocybin dose of 25 mg. At 25 mg, the mean psilocin C_{max} is about
336 18.7 ng/mL, with an associated ΔQTc of 2.1 ms (and 90% upper confidence level mean of 6.6
337 ms). Therefore, while psilocybin does have an effect on QTc interval, at therapeutic doses, the
338 increase is not cause for clinical concern (Dahmane et al., 2021). Our study did not show a
339 significant change in QTc interval, thus providing further evidence that, in healthy individuals,
340 QTc prolongation is not a significant concern. The only atypical occurrence seen on three
341 participants' ECGs were ventricular extrasystoles, which resolved by the following reading.
342 These are not considered clinically significant, as ventricular extrasystoles only become a cause
343 for concern if they occur frequently or are symptomatic. No ventricular extrasystoles were seen
344 on the eight-week follow-up ECGs.

345
346 Clearly, some individuals will experience blood pressure elevations during psilocybin use that
347 extend into the hypertensive range; however, because such elevations are transient and
348 manageable, we do not consider this clinically significant. The cardiovascular system is resilient
349 enough to endure this brief increase, similarly to which both systolic blood pressure and heart
350 rate increase during aerobic exercise (Cohen & Townsend, 2007). This research is also supported
351 by emergency medicine studies that show no adverse outcomes in individuals presenting with
352 hypertension to the Emergency Department in the ensuing two years (McAlister et al., 2021). As
353 described by Alley & Copelin (2022), in general, it is normally not necessary to treat
354 hypertensive urgencies, and it is often advised against due to the danger of unnecessary rapid
355 correction that could lead to hypoperfusion. Virtually all episodes of hypertension with
356 psilocybin use are without end-organ damage and do not require treatment.

357
358 If hypertension presents with symptoms of end-organ damage, such as headache, dizziness,
359 shortness of breath, chest pain, vomiting, or vision changes, then further evaluation is required
360 (Alley & Copelin, 2022). End-organ damage secondary to hypertension generally requires
361 intravenous treatment, and therefore, transfer to the Emergency Department is required; it would
362 be advisable to give an oral antihypertensive agent while waiting for transport. However, for
363 most patients who experience hypertension due to drug effect, blood pressure will rapidly correct
364 itself, especially with the administration of a benzodiazepine if warranted. As seen with one of
365 the participants in our study, blood pressure increased to 193/108 mmHg during an emotionally
366 intense period; this participant did not show symptoms of end-organ damage, and as expected,
367 blood pressure corrected itself to 157/99 mmHg after 25 minutes, without pharmacological

368 intervention. This participant's peak blood pressure is an outlier in this study, as demonstrated by
369 Figure 1 and Figure 2.

370
371 For context, despite significant clinical research, there are no examples of significant adverse
372 physiological events, and despite extensive and longstanding recreational use, there is very scant
373 evidence of associated physiological adversity. Adverse physiological effects that have occurred
374 are generally a result of the concomitant use of other recreational drugs, including alcohol. We
375 would hypothesize that use of psilocybin in the clinical setting would further diminish the risk of
376 adverse physical outcomes. The only case of psilocybin intoxication resulting in cardiovascular
377 dysfunction that we could find in the literature is described by Borowiak, Ciechanowski, &
378 Waloszczuk (1998). This case described an 18-year-old man who was hospitalized following
379 seizures and cardiopulmonary arrest after consumption of *Psilocybe semilanceata* mushrooms –
380 the species of *Psilocybe* mushrooms containing the highest psilocybin concentration. This
381 individual reported frequent psilocybin use, and investigations eventually revealed Wolff-
382 Parkinson-White syndrome, which presumably contributed to arrhythmia (SVT) and myocardial
383 infarction following use of the drug in this case. This individual had frequently consumed an
384 unknown amount of a potent species of mushroom without prior evaluation from his physician –
385 such uncontrolled conditions would not occur in a clinical setting.

386
387 Therefore, it would seem that psilocybin has a remarkably benign cardiovascular safety profile,
388 and we expect that apparently healthy individuals can safely tolerate the therapeutic use of
389 psilocybin without laboratory investigations or complete physical examinations. This will
390 increase the accessibility of this treatment for many patients, without significantly compromising
391 safety. Blood pressure assessment is a simple screening measure to conduct for all individuals
392 seeking psilocybin-assisted therapy; however, we discourage measuring blood pressure prior to
393 psilocybin ingestion on the day of treatment for several reasons. First, blood pressure is easily
394 affected by anxiety; it can add another layer of stress if the message is that the patient will not be
395 able to proceed with the treatment session if his/her blood pressure is too high. Second, in terms
396 of maximizing efficacy, the process should not be over-medicalized.

397
398 Some basic screening measures are appropriate for individuals with known cardiovascular
399 disease, poor exercise tolerance, or on QTc prolonging medications. In the case of those on QTc
400 prolonging medications or those with known QTc concerns, an ECG and electrolyte panel should
401 be performed prior to psilocybin administration. Any patient with uncontrolled hypertension or
402 exercise-induced myocardial ischemia should have these concerns treated prior to psilocybin
403 administration. Bloodwork (sodium, potassium, bicarbonate, urea, creatinine, calcium, and
404 magnesium) should be conducted in those with abnormal or borderline ECGs, on diuretics, or
405 with malnourishment. While thorough screening is necessary to attenuate the risk of adverse
406 events from occurring in the first place, practitioners should have rescue medication (e.g.,
407 labetalol, nitroglycerin, and lorazepam and/or diazepam) on hand in the unlikely event a
408 hypertensive emergency (or intense anxiety/agitation) occurs. Thus far, research and historical
409 experience does not suggest that antipsychotic medications have a role in the acute setting.

410
411 The secondary outcome of our study was to assess the psychological effects of psilocybin; the
412 specific psychological outcomes assessed were mood and mystical experience. The QIDS-SR16
413 was administered to participants on four occasions to evaluate mood: two days before the

414 psilocybin session to obtain a baseline score, as well as two days, seven days, and eight weeks
415 after the psilocybin session. Although the mean scores on days two, seven, and week eight were
416 all lower than baseline ($M = 3.50$, $SD = 2.35$), only week eight showed a statistically significant
417 lower score ($M = 1.86$, $SD = 0.86$). The QIDS-SR16 is a self-administered questionnaire that
418 evaluates depressive symptomatology and correlates with the nine DSM-IV symptom criteria for
419 depression; it is scored from 0-27, with higher scores indicating more severe depressive
420 symptoms. Scores from 0-5 indicate no depression, 6-10 indicate mild depression, 11-15
421 moderate depression, 16-20 severe depression, and 21-27 very severe depression. Although a
422 statistically significant decrease was seen from baseline to week eight, it does not represent a
423 clinically significant difference when the overall scoring of the questionnaire is considered. This
424 scale is designed to measure depression, whereas only one out of 14 participants' baseline scores
425 crossed the threshold for depression (with a score of 10). The mean scores of 3.50 at baseline and
426 1.86 at week-eight both signify no depression. As such, a limitation of our study was that this
427 questionnaire was not the most sensitive tool to assess mood in healthy participants. A
428 questionnaire that assesses mental well-being, such as the Brief Index of Self-actualization
429 (BISA) revised, is likely a more appropriate tool to use to assess healthy participants;
430 measurements of self-actualization are based on the idea that mental well-being should consider
431 more than just the absence of disease, and should examine the extent to which personal potential
432 is realized and achieved (Sumerlin & Bundrick, 1998). However, given the decrease in QIDS-
433 SR16 scores in participants not suffering from clinical depression, we hypothesize that a
434 commensurate or greater decrease would be seen in those suffering from depressive disorders.
435

436 Despite the fact that the QIDS-SR16 was not a sensitive tool for the assessment of mood in
437 healthy participants, there are several clinically useful conclusions that can be drawn from the
438 scores observed in our study. Although only experienced by a minority of participants ($n = 3$), it
439 is important for practitioners to recognize the possibility that depressive symptoms may
440 temporarily increase during the first week following a psilocybin treatment. Therefore,
441 practitioners should follow-up with their clients during this time to ensure their well-being. It is
442 widely accepted that this is a fertile time period for integration of the psychedelic experience,
443 and it is hypothesized that the associated neuroplastic effects of psilocybin may help instantiate
444 the therapeutic effects of therapy during this timeframe. With therapy, the brain can retain the
445 new neural connections that the psychedelic state has cultivated. Essentially, in addition to the
446 psilocybin-induced insights and biological changes that occur as a result of the acute drug
447 effects, psilocybin also primes the brain for learning and healing in the weeks immediately
448 following psilocybin use.
449

450 The MEQ-30 was the tool used to evaluate another subjective effect induced by psilocybin – the
451 mystical experience. It is a 30-question, self-report questionnaire that assesses four different
452 factors of the mystical experience: mysticism, positive mood, transcendence of space and time,
453 and ineffability. Each question is scored on a scale of 0-5 and the final score is an average of all
454 30 questions. A score ≥ 3 represents a full mystical experience. In studies to date, the mystical
455 experience appears to be positively associated with the therapeutic effects of psilocybin, and it is
456 ultimately the combination of both physiological modifications in the brain and emotionally
457 meaningful insights that drive the transformational changes that the patient experiences
458 (Gukasyan & Nayak, 2021).
459

460 In our study, the MEQ-30 was completed on days two and seven after the psilocybin session.
461 Participants' perception of their mystical experience (or lack thereof) was not significantly
462 different between the two measurements. Only three of 14 participants did not score ≥ 3 . The
463 mystical experience is often determined by "set" (factors related to the individual's mindset as
464 they enter the psychedelic session, including idiosyncratic personality dynamics, mood, past
465 experiences, and expectations of the psilocybin experience), "setting" (the environment in which
466 the psilocybin session occurs, including the cultural, physical, and social environment), dose, and
467 individual pharmacokinetic characteristics (Hartogsohn, 2016). A 25 mg dose of psilocybin is
468 equivalent to approximately 4-5 g of dried *Psilocybe cubensis* mushrooms (Haden, 2020). We
469 speculate that one of our participants is a fast metabolizer of psilocybin, due to the fact that this
470 participant only had a 30-minute experience, characterized by relaxation but not by the typical
471 psychedelic effects. Of note, while this participant did not have a mystical experience, an
472 increase in well-being was still described.

473
474 During the eight-week follow-up appointments, participants described the common experience of
475 feeling "better," "happier," and "lighter" after the psilocybin session, despite not having
476 perceived themselves as anxious prior to the session. Participants suggested that they had
477 previously become accustomed to their prior levels of anxiety, as they did not have a reference
478 point for comparison. After experiencing improvements in their mental well-being following
479 psilocybin use, many participants felt optimistic that they would experience a greater sense of
480 well-being in the future.

481 482 **Conflict of Interest**

483 Jennifer N. Bennett is a Medical Writer and Research Assistant at ATMA Journey Centers Inc.
484 Michael D. Blough is the Chief Science Officer at ATMA Journey Centers Inc. Ravinder Bains
485 is the Chief Medical Officer at ATMA Journey Centers Inc. Lyle Galloway is a Medical Advisor
486 at ATMA Journey Centers Inc. Ian Mitchell is an instructor for the ATMA Journey Centers Inc.
487 Introduction to Psychedelic-Assisted Therapy course.

488 489 **Author Contributions**

490
491 JB, MB, RB, LG contributed to the conception and design of the study. JB organized the
492 database. JB performed the statistical analysis. JB wrote the first draft of the manuscript. JB, RB,
493 IM wrote sections of the manuscript. All authors contributed to manuscript revision, and read
494 and approved the submitted version.

495 496 **Funding**

497
498 This study was funded by ATMA Journey Centers Inc.

499 500 **Acknowledgments**

501
502 We would like to thank The Newly Institute for the use of their facilities.

503
504 We would like to thank Natalie Bergstrom and Debbie White for their involvement in participant
505 intake and data collection.

506 Figure 1: Comparison of baseline MAP to peak MAP during the psilocybin session for each
 507 participant.

508
 509 Figure 2: Comparison of each participant’s baseline SBP to the average and peak SBPs during
 510 the psilocybin session.

511
 512 Figure 3: Comparison of each participant’s baseline DBP to the average and peak DBPs during
 513 the psilocybin session.

514
 515 Table 1: Participants’ demographic information.

Characteristic	n = 14
Age, range (mean, SD)	32-64 (46, 10.33)
Gender, n (%)	
Female	11 (78.6)
Male	3 (21.4)
Designations, n (%)	
Registered Nurse	3 (21.4)
Registered Psychiatric Nurse	1 (7.1)
Occupational Therapist	1 (7.1)
Registered Social Worker	3 (21.4)
Registered Psychologist	4 (28.6)
Registered Clinical Counsellor	1 (7.1)
Registered Psychotherapist	1 (7.1)

516
 517
 518 Table 2: Summary of vital signs (primary outcome) and psychological questionnaires (secondary
 519 outcome).

			Mean	SD	Range	Reference Range
Primary Outcomes	MAP (mmHg)	Baseline	91.55	7.59	79.67 - 104	70 - 100
		Peak Psilocybin*	110.76	12.15	93.33 - 126.67	
	Blood Pressure (mmHg)	Baseline SBP	121.5	11.59	102 - 140	90 - 120
		Baseline DBP	76.57	7.38	62 - 89	60 - 80
		Peak SBP*	145.93	19.01	126 - 193	
		Peak DBP*	93.93	9.75	77 - 109	
		Average SBP*	133.03	13.68	116.6 - 163.25	
	Average DBP*	86.44	8.08	77 - 102.88		
	Heart Rate	Baseline	68.43	7.94	56 - 84	60 - 100

(bpm)	Peak Heart Rate*	91.57	17.25	78 - 143	
	Average Heart Rate*	81.21	11.91	72.83 - 112.8	
QTc Interval (msec)	Baseline	419.21	19.37	392 - 453	350 - 460
	Maximum Psilocybin	406.64	16.76	366 - 437	
Temperature(°C)	Psilocybin	36.85	0.32	35.9 - 37.5	36.1 - 37.2
Secondary Outcomes					Scoring
QIDS-SR16	Baseline	3.50	2.35	1 - 11	6 - 10 mild
	Day Two	3.29	2.27	1 - 12	11 - 15 moderate
	Day Seven	2.21	1.67	0 - 9	16 - 20 severe
	Week Eight*	1.86	0.86	1 - 6	≥21 very severe
MEQ-30	Day Two	3.77	0.8	2.6 - 4.93	≥3 full mystical experience
	Day Seven	3.67	0.94	2.2 - 4.93	

* denotes a statistically significant difference compared to baseline

520
521 Table 3: Total number of adverse events (out of 14 participants) occurring two days, seven days,
522 and eight weeks after the psilocybin session.

Adverse Event	Mild	Moderate	Severe	Life-threatening	Fatal
2 days post-psilocybin					
Nausea	3				
Vomiting					
Headache	2	3	1		
Anxiety	1				
Confusion	2				
Temporary fatigue or difficulty sleeping throughout the night	3	1			
Anxiety, mania, or psychotic symptoms					
Other					
7 days post-psilocybin					
Nausea					
Vomiting					
Headache					
Anxiety	1				
Confusion					
Fatigue					

Anxiety, mania, or psychotic symptoms					
Other					
8 weeks post-psilocybin					
Nausea					
Vomiting					
Headache					
Anxiety					
Confusion					
Fatigue					
Anxiety, mania, or psychotic symptoms					
Other					

523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552

References

- 553
554
555 Alley, W. D., & Copelin, I. E. (2022). Hypertensive Urgency. In StatPearls.
556 <https://www.ncbi.nlm.nih.gov/pubmed/30020723>
557
- 558 Borowiak, K. S., Ciechanowski, K., & Waloszczyk, P. (1998). Psilocybin mushroom (*Psilocybe*
559 *semilanceata*) intoxication with myocardial infarction. *J Toxicol Clin Toxicol*, *36*(1-2), 47-49.
560 <https://doi.org/10.3109/15563659809162584>
561
- 562 Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018). Double-blind comparison of
563 the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in
564 subjective experiences. *Psychopharmacology*, *235*(2), 521-534. [https://doi.org/10.1007/s00213-](https://doi.org/10.1007/s00213-017-4769-4)
565 [017-4769-4](https://doi.org/10.1007/s00213-017-4769-4)
566
- 567 Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past,
568 Present, and Future. *Neuropsychopharmacology*, *42*(11), 2105-2113.
569 <https://doi.org/10.1038/npp.2017.84>
570
- 571 Cohen, D. L., & Townsend, R. R. (2007). Exaggerated Systolic Blood Pressure Response To Exercise.
572 *The Journal of Clinical Hypertension*, *9*(4), 291-292.
573 <https://doi.org/https://doi.org/10.1111/j.1524-6175.2007.06272.x>
574
- 575 Dahmane, E., Hutson, P. R., & Gobburu, J. V. S. (2021). Exposure-Response Analysis to Assess the
576 Concentration-QTc Relationship of Psilocybin/Psilocin. *Clin Pharmacol Drug Dev*, *10*(1), 78-
577 85. <https://doi.org/10.1002/cpdd.796>
578
- 579 Daniel, J., & Haberman, M. (2017). Clinical potential of psilocybin as a treatment for mental health
580 conditions. *Ment Health Clin*, *7*(1), 24-28. <https://doi.org/10.9740/mhc.2017.01.024>
581
- 582 DEA. (2020). Psilocybin. *Drug Fact Sheet*. [https://www.dea.gov/sites/default/files/2020-](https://www.dea.gov/sites/default/files/2020-06/Psilocybin-2020_0.pdf)
583 [06/Psilocybin-2020_0.pdf](https://www.dea.gov/sites/default/files/2020-06/Psilocybin-2020_0.pdf)
584
- 585 Gukasyan, N., & Nayak, S. M. (2022). Psychedelics, placebo effects, and set and setting: Insights from
586 common factors theory of psychotherapy. *Transcultural Psychiatry*, *59*(5), 652-664.
587 <https://doi.org/10.1177/1363461520983684>
588
- 589 Haden, M. (2020). *Manual for Psychedelic Guides*.
- 590 Hartogsohn, I. (2016). Set and setting, psychedelics, and the placebo response: An extra-
591 pharmacological perspective on psychopharmacology. *J Psychopharmacol*, *30*(12), 1259-
592 1267. <https://doi.org/10.1177/0269881116677852>
- 593
594 Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004). Acute psychological
595 and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled

- 596 dose-effect study. *Psychopharmacology (Berl)*, 172(2), 145-156. <https://doi.org/10.1007/s00213->
597 003-1640-6
598
599 Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The
600 Therapeutic Potential of Psilocybin. *Molecules*, 26(10).
601 <https://doi.org/10.3390/molecules26102948>
602
603 McAlister, F. A., Youngson, E., & Rowe, B. H. (2021). Elevated blood pressures are common in the
604 emergency department but are they important? A retrospective cohort study of 30,278 adults.
605 *Ann Emerg Med*, 77(4), 425-432. <https://doi.org/10.1016/j.annemergmed.2020.11.005>
606
607 McCulloch, D. E. W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S.,
608 Knudsen, G. M., & Fisher, P. M. (2022). Lasting effects of a single psilocybin dose on resting-
609 state functional connectivity in healthy individuals. *Journal of psychopharmacology (Oxford,*
610 *England)*, 36(1), 74-84. <https://doi.org/10.1177/02698811211026454>
611
612 Rossi, G. N., Hallak, J. E. C., Bouso Saiz, J. C., & Dos Santos, R. G. (2022). Safety issues of psilocybin
613 and LSD as potential rapid acting antidepressants and potential challenges. *Expert Opin Drug*
614 *Saf*, 21(6), 761-776. <https://doi.org/10.1080/14740338.2022.2066650>
615
616 Siegel, A. N., Meshkat, S., Benitah, K., Lipsitz, O., Gill, H., Lui, L. M. W., Teopiz, K. M., McIntyre, R.
617 S., & Rosenblat, J. D. (2021). Registered clinical studies investigating psychedelic drugs for
618 psychiatric disorders. *J Psychiatr Res*, 139, 71-81.
619 <https://doi.org/10.1016/j.jpsychires.2021.05.019>
620
621 Sumerlin, J. R., & Bundrick, C. M. (1998). REVISION OF THE BRIEF INDEX OF SELF-
622 ACTUALIZATION. *Perceptual and Motor Skills*, 87, 115-125.
623
624 Yu, C.-L., Liang, C.-S., Yang, F.-C., Tu, Y.-K., Hsu, C.-W., Carvalho, A. F., Stubbs, B., Thompson, T.,
625 Tsai, C.-K., Yeh, T.-C., Yang, S.-N., Shin, J. I., Chu, C.-S., Tseng, P.-T., & Su, K.-P. (2022).
626 Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A
627 Systematic Review and Multivariate Meta-Analysis. *Journal of Clinical Medicine*, 11(4), 938.
628 <https://www.mdpi.com/2077-0383/11/4/938>
629

630 **Data Availability Statement**

631
632 The original datasets presented in the study are available in a publicly accessible repository. This
633 data can be found here: <https://doi.org/10.6084/m9.figshare.22329433.v1>

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.12.23288325>; this version posted April 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).





